These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2789150)

  • 1. Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.
    Símová J; Bubeník J; Voitenok NN; Gren E
    Folia Biol (Praha); 1989; 35(3):137-42. PubMed ID: 2789150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.
    Bubeník J; Kieler J; Indrová M
    Folia Biol (Praha); 1986; 32(3):209-11. PubMed ID: 3488924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
    Bubeník J; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
    Silagi S; Schaefer AE
    J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour efficacy of IL-1 and IL-2.
    Bubeník J; Indrová M; Holán V
    Folia Biol (Praha); 1988; 34(1):42-7. PubMed ID: 3260564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2.
    Indrová M; Bubeník J; Toulcová A
    Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy of cancer: cyclophosphamide-resistant tumour cells are equally sensitive as the original tumour cell population to local IL-2 immunotherapy.
    Símová J; Bubeník J; Jandlová T
    Folia Biol (Praha); 1992; 38(2):122-8. PubMed ID: 1526289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
    Salup RR; Wiltrout RH
    Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active suppression of the proliferative response to interleukin-2 in tumour-bearing mice.
    Zajícová A; Holán V
    Folia Biol (Praha); 1990; 36(6):301-11. PubMed ID: 2279584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy using local interleukin 2 administration.
    Bubeník J; Indrová M
    Immunol Lett; 1987 Dec; 16(3-4):305-9. PubMed ID: 3502122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
    Krupke DM; Fuller J; Aslakson C; Evans R
    Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM; Renes IB; Rutgers DH; Everse LA; Bernsen MR; Den Otter W; Battermann JJ
    Radiat Oncol Investig; 1997; 5(2):54-61. PubMed ID: 9303058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.